AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14611917 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant chemoradiotherapy
Number of subjects: 0
Study 14611917 — intervention group
Group type: COMPARATOR
Intervention: Sequential platinum-based chemoradiotherapy
Number of subjects: 0
Study 14611917 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced radiotherapy techniques, novel chemotherapy combinations, induction chemotherapy, and consolidation chemotherapy with concomitant chemoradiotherapy
Number of subjects: 0
Study 14611917 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular therapies integrated with chemoradiotherapy
Number of subjects: 0
Study 10960397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Number of subjects: 100
Study 10960397 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine (50 mg) with intraperitoneal bupivacaine (80 mL of 0.125% with 1:200,000 epinephrine)
Number of subjects: 100
Study 8993768 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-B1
Number of subjects: 30
Study 8993768 — intervention group
Group type: EXPERIMENTAL
Intervention: TF-PBL
Number of subjects: 30
Study 8993768 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 30
Study 1535505 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day 4‐HPR for 5 years
Number of subjects: 3500
Study 1535505 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 3500
Study 6398628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/day for 14 days with tapering and discontinuation by day 21)
Number of subjects: 27
Study 6398628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 6398628 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 27
Study 30513377 — intervention group
Group type: EXPERIMENTAL
Intervention: 34 Gy in 1 fraction
Number of subjects: 84
Study 30513377 — intervention group
Group type: COMPARATOR
Intervention: 48 Gy in 4 fractions
Number of subjects: 84
Study 31462466 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional abilities training programme
Number of subjects: 62
Study 31462466 — intervention group
Group type: COMPARATOR
Intervention: Usual educational intervention (Control)
Number of subjects: 62
Study 28683796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin group (750 mg/day metformin + 5 mg/day dapagliflozin)
Number of subjects: 80
Study 28683796 — intervention group
Group type: COMPARATOR
Intervention: Metformin group (1500 mg/day metformin)
Number of subjects: 80
Study 28683796 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin group
Number of subjects: 80
Study 25085686 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 90
Study 25085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg kg(‐1)
Number of subjects: 90
Study 25085686 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 µg kg(‐1)
Number of subjects: 90
Study 23751405 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous cystolithotripsy within a laparoscopic entrapment bag and TURP by two surgeons simultaneously
Number of subjects: 76
Study 23751405 — intervention group
Group type: COMPARATOR
Intervention: Transurethral cystolithotripsy followed by TURP
Number of subjects: 76
Study 21316855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 to 600 mg/day
Number of subjects: 219
Study 21316855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 21316855 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 219
Study 19595104 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE+HIFU
Number of subjects: 68
Study 19595104 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 68
Study 16573707 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 5 inhibitors (PDE5-Is)
Number of subjects: 0
Study 16573707 — intervention group
Group type: COMPARATOR
Intervention: Selective-serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 16573707 — intervention group
Group type: COMPARATOR
Intervention: Behavioural therapy
Number of subjects: 0
Study 12773645 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg twice daily) plus optimized background regimen
Number of subjects: 512
Study 12773645 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimized background regimen alone)
Number of subjects: 512
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 200
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Research in emergency situations
Number of subjects: 200
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Research associated with risk or discomfort greater than standard treatment
Number of subjects: 200
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sheets
Number of subjects: 200
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental involvement in informed consent process
Number of subjects: 200
Study 11145490 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician agreement on informed consent process
Number of subjects: 200
Study 9033327 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 42
Study 9033327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 42
Study 8314418 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with CADN
Number of subjects: 1171
Study 8314418 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with CADN
Number of subjects: 1171
Study 8314418 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients with peripheral neuropathy
Number of subjects: 1171
Study 8314418 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with peripheral neuropathy
Number of subjects: 1171
Study 3560028 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon preparation involving wash-out enemas
Number of subjects: 185
Study 3560028 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon preparation involving laxatives
Number of subjects: 185
Study 3560028 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon preparation involving residue-free diet
Number of subjects: 185
Study 3560028 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of all three methods (residue-free diet, laxatives, wash-out enemas)
Number of subjects: 185
Study 3560028 — intervention group
Group type: COMPARATOR
Intervention: Control group (other colon preparations)
Number of subjects: 185
Study 30160530 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga (30-min sessions at 30, 32, 34, 36, 37, 38, and 39 weeks of gestation)
Number of subjects: 200
Study 30160530 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated yoga
Number of subjects: 200
Study 27027541 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine treatment for 3 weeks
Number of subjects: 19
Study 24772504 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved patient compliance before treatment
Number of subjects: 350
Study 24772504 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment without compliance improvement)
Number of subjects: 350
Study 22535855 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (up to 5 weekly messages)
Number of subjects: 9213
Study 22535855 — intervention group
Group type: COMPARATOR
Intervention: Usual care (automated telephone reminder and informational flyers)
Number of subjects: 9213
Study 20574268 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous adductor longus tenotomy (PAT)
Number of subjects: 27
Study 20574268 — intervention group
Group type: COMPARATOR
Intervention: Open adductor longus tenotomy (OAT)
Number of subjects: 27
Study 19033823 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabrachial Lys‐[Leu8]‐des‐Arg9‐bradykinin (B1 antagonist)
Number of subjects: 16
Study 19033823 — intervention group
Group type: EXPERIMENTAL
Intervention: Lys‐des‐Arg9‐bradykinin (B1 agonist)
Number of subjects: 16
Study 19033823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bradykinin (B2 agonist)
Number of subjects: 16
Study 19033823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (endothelium‐independent vasodilator)
Number of subjects: 16
Study 19033823 — intervention group
Group type: COMPARATOR
Intervention: HOE‐140 (B2 antagonist)
Number of subjects: 16
Study 15988423 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol
Number of subjects: 129
Study 15988423 — intervention group
Group type: COMPARATOR
Intervention: Levalbuterol
Number of subjects: 129
Study 12651680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (25 microg initial dose, testing interval 1 microg)
Number of subjects: 66
Study 12651680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (125 microg initial dose, testing interval 5 microg)
Number of subjects: 66
Study 12651680 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil/Fentanyl potency ratio
Number of subjects: 66
Study 9895070 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA/TCI (propofol-based TCI system and continuous administration of remifentanil)
Number of subjects: 60
Study 9895070 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (inhaled anesthesia with isoflurane, fentanyl, and N2O)
Number of subjects: 60
Study 9895070 — intervention group
Group type: COMPARATOR
Intervention: Standard propofol (fentanyl and N2O with continuous infusion of propofol using a standard delivery system)
Number of subjects: 60
Study 8887038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intraperitoneal aprotinin treatment (aprotinin group, n = 22)
Number of subjects: 48
Study 8887038 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26, not treated with aprotinin)
Number of subjects: 48
Study 8887038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (aprotinin and control)
Number of subjects: 48
Study 1818424 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN maintenance therapy (3 x 10(6) I.U. INTRON‐A by subcutaneous injection three times a week for 4 months)
Number of subjects: 21
Study 1818424 — intervention group
Group type: COMPARATOR
Intervention: Vitamins (control group)
Number of subjects: 21
Study 7193447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration of methotrexate (50 mg/sq m orally) and cisplatin (intravenously 24 hours later), repeated four times at weekly intervals.
Number of subjects: 82
Study 7193447 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic postoperative radiation therapy (for 43 patients operated on).
Number of subjects: 82
Study 7193447 — intervention group
Group type: COMPARATOR
Intervention: Observation only (for patients randomly selected after surgery and/or radiation therapy).
Number of subjects: 82
Study 31901082 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 40
Study 31901082 — intervention group
Group type: COMPARATOR
Intervention: Canola oil
Number of subjects: 40
Study 31222909 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 925
Study 31222909 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 925
Study 31222909 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 925
Study 31222909 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding WC or WHtR on top of BMI
Number of subjects: 925
Study 28052570 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth Fit 4 Life (YF4L) treatment group
Number of subjects: 141
Study 28052570 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical care)
Number of subjects: 141
Study 25724784 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829
Study 25724784 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829
Study 25724784 — intervention group
Group type: COMPARATOR
Intervention: Composite event of death (D) and nonfatal Q-wave myocardial infarction (MI)
Number of subjects: 1829
Study 25724784 — intervention group
Group type: COMPARATOR
Intervention: Nonfatal MI
Number of subjects: 1829
Study 25111438 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide ablative fractional laser (AFL)
Number of subjects: 14
Study 25111438 — intervention group
Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 14
Study 25111438 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PDL and AFL
Number of subjects: 14
Study 25111438 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall improvement measured by the Vancouver Scar Scale
Number of subjects: 14
Study 18248343 — intervention group
Group type: EXPERIMENTAL
Intervention: Free semiannual preventive dental care
Number of subjects: 498
Study 15020036 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg
Number of subjects: 1000
Study 15020036 — intervention group
Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg
Number of subjects: 1000
Study 15020036 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study 11740295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 800 mg, administered two times daily for 3 days before exercise tests
Number of subjects: 12
Study 11740295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Beighton score measurement in group I (n = 252)
Number of subjects: 910
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Beighton score measurement in group II (n = 658)
Number of subjects: 910
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of hypermobility between genders in group II
Number of subjects: 910
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related hypermobility assessment
Number of subjects: 910
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of hypermobility at non-dominant body side
Number of subjects: 910
Study 9228503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetelet-index relation to hypermobility
Number of subjects: 910
Study 8093705 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol
Number of subjects: 20
Study 8093705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3307414 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg/day
Number of subjects: 29
Study 3307414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 11320918 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated core biopsy
Number of subjects: 52
Study 11320918 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration cytology
Number of subjects: 52
Study 31537908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and trabectedin every 21 days (Arm BT)
Number of subjects: 71
Study 31537908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab, trabectedin and carboplatin every 28 days (Arm BT+C)
Number of subjects: 71
Study 30302441 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-nanofilled composite
Number of subjects: 40
Study 30302441 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofilled composite
Number of subjects: 40
Study 30302441 — intervention group
Group type: EXPERIMENTAL
Intervention: Microhybrid composite
Number of subjects: 40
Study 30302441 — intervention group
Group type: COMPARATOR
Intervention: Dental tissues
Number of subjects: 40
Study 26646759 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel (40 mg/day; 80 mg/m²/week)
Number of subjects: 202
Study 26646759 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 202
Study 26646759 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel
Number of subjects: 202
Study 25089351 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (docosahexaenoic acid and eicosapentaenoic acid)
Number of subjects: 36
Study 25089351 — intervention group
Group type: COMPARATOR
Intervention: No omega-3 supplementation
Number of subjects: 36
Study 25089351 — intervention group
Group type: COMPARATOR
Intervention: Anti-VEGF treatment-naïve
Number of subjects: 36
Study 25089351 — intervention group
Group type: COMPARATOR
Intervention: Epiretinal membrane or macular hole
Number of subjects: 36
Study 22348256 — intervention group
Group type: COMPARATOR
Intervention: Dabigatran etexilate 150 mg alone (treatment A)
Number of subjects: 24
Study 22348256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 7 days of rifampicin (treatment B)
Number of subjects: 24
Study 22348256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 7 days washout (treatment C)
Number of subjects: 24
Study 22348256 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 14 days washout (treatment D)
Number of subjects: 24
Study 20801444 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol
Number of subjects: 0
Study 20801444 — intervention group
Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 0
Study 17078981 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine (300 mg/kg body weight)
Number of subjects: 15
Study 17078981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no tyrosine)
Number of subjects: 15
Study 17078981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water trials (both TYR and PLB)
Number of subjects: 15
Study 17078981 — intervention group
Group type: COMPARATOR
Intervention: Control (warm water at 35 degrees C)
Number of subjects: 15
Study 16215602 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acids supplement for 8 weeks
Number of subjects: 55
Study 16215602 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement for 8 weeks
Number of subjects: 55
Study 12164090 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2 months treatment)
Number of subjects: 8
Study 12164090 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (intra-arterial infusion)
Number of subjects: 8
Study 12164090 — intervention group
Group type: COMPARATOR
Intervention: Co-infusion of L-NMMA (inhibitor of nitric oxide synthase)
Number of subjects: 8
Study 9931520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (10.5 microg/kg over a 1-hour period followed by 1.5 microg/kg/hr)
Number of subjects: 163
Study 9931520 — intervention group
Group type: COMPARATOR
Intervention: Morphine (140 microg/kg over a 1-hour period followed by 20 microg/kg/hr)
Number of subjects: 163
Study 9931520 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 163
Study 9931520 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 163
Study 9454229 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with larynx carcinoma
Number of subjects: 30
Study 9454229 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 30
Study 1968694 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium (0.03 mg/kg)
Number of subjects: 250
Study 1968694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine (0.05 mg/kg)
Number of subjects: 250
Study 1968694 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.01 mg/kg)
Number of subjects: 250
Study 1968694 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.04 mg/kg)
Number of subjects: 250
Study 1968694 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 250
Study 1968694 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (control)
Number of subjects: 250
Study 373959 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic standardization procedures
Number of subjects: 0
Study 373959 — intervention group
Group type: EXPERIMENTAL
Intervention: Examiner variance monitoring
Number of subjects: 0
Study 31648505 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol including electrolyte solution administration, intraoperative warming, controlled infusion volume, and multi-mode analgesia.
Number of subjects: 86
Study 31648505 — intervention group
Group type: COMPARATOR
Intervention: Traditional interventions (Control group).
Number of subjects: 86
Study 27445072 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide/timolol fixed combination (group A)
Number of subjects: 44
Study 27445072 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide/brimonidine fixed combination (group B)
Number of subjects: 44
Study 26522035 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) alone
Number of subjects: 32
Study 26522035 — intervention group
Group type: COMPARATOR
Intervention: Mini-implant anchored Forsus Fatigue Resistant Device (FMI)
Number of subjects: 32
Study 23377333 — intervention group
Group type: EXPERIMENTAL
Intervention: Scar product (twice-daily application)
Number of subjects: 28
Study 23377333 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum (standard of care)
Number of subjects: 28
Study 23377333 — intervention group
Group type: EXPERIMENTAL
Intervention: Scar product
Number of subjects: 28
Study 22013378 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction by video using the iPod Touch
Number of subjects: 22
Study 22013378 — intervention group
Group type: COMPARATOR
Intervention: No instruction by video
Number of subjects: 22
Study 19462698 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed patients in the same NYHA class
Number of subjects: 1495
Study 19462698 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 1495
Study 17580596 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 702
Study 17580596 — intervention group
Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 702
Study 17580596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 15197199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet intervention
Number of subjects: 291